Home
OverviewAbout10 LeapsCollaborationImpact
OverviewLeaps TalksChapter FilmsLeaps.orgPartners
AgricultureHealth
OverviewAnnual ReviewBreakthrough StudyPress ReleasesIn the NewsReportsLeaps LeadershipPress KitMedia Contact
Team
  • Approach
    • Overview
    • About
    • 10 Leaps
    • Collaboration
    • Impact
  • Engagement
    • Overview
    • Leaps Talks
    • Chapter Films
    • Leaps.org
    • Partners
    • Agriculture
    • Health
  • News
    • Overview
    • Annual Review
    • Breakthrough Study
    • Press Releases
    • In the News
    • Reports
    • Leaps Leadership
    • Press Kit
    • Media Contact
  • Team
ContactImprintPrivacy StatementConditions of Use
sign up for our newsletter
see more companies

SonoThera

Logo

Vision

SonoThera is dedicated to developing the next generation of genetic medicines to treat the root cause of human diseases.

Approach

SonoThera is developing an ultrasound-mediated nonviral genetic medicine platform designed to deliver the next generation of safe, targeted, and redosable genetic medicines. By integrating proprietary RIPPLE™ ultrasound delivery with PORE™ payload engineering, the company is advancing a broad range of genetic medicine approaches, including DNA and RNA therapeutics, gene editing, and gene silencing. SonoThera's platform is designed to enable precise, durable gene expression across multiple tissues while addressing key limitations associated with viral delivery approaches. The company is advancing a pipeline of genetic medicines for serious diseases, including Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease.

SonoThera is addressing

  • Leap 01 / Cure genetic diseases

CEO:

Kenneth Greenberg, PhD

Founders:

Kenneth Greenberg, PhD

Steve Feinstein, MD

Michael H. Davidson, MD, FAAC

First investment:

June 2026

sonothera.com